<

AQUIS STOCK EXCHANGE Aquis Stock Exchange: Application for Admission Announcement

Transparency directive : regulatory news

06/07/2023 08:00

Aquis Stock Exchange
Aquis Stock Exchange: Application for Admission Announcement

06-Jul-2023 / 07:00 GMT/BST
The issuer is solely responsible for the content of this announcement.


 

ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQUIS GROWTH MARKET

 

 

APPLICANT NAME:

Blackpoint Biotech PLC

APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:

48-49 Chancery Lane, C/O Keystone Law, London, England, WC2A 1JF

+44 208 050 6458

DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):

  • Michael William Balfour, Non-Executive Chairman
  • David Manuel Martinez, Chief Executive Officer
  • Alexander James Robert Stormont Wakeford, Chief Financial Officer
  • Dr Michael Barry Mayne, Chief Product Officer 

APPLICANT SECTOR:

Healthcare

DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:

Blackpoint Biotech PLC is a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing.

NAME OF AQUIS CORPORATE ADVISER:

First Sentinel Corporate Finance Limited

NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:

12,187,179 Ordinary Shares of £0.005 each

SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):

15.12%

SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT’S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:

 

Shareholder

Shares

Pre-admission

%

Pre-admission

Shares

Post-admission

%

Post-admission

David Martinez

4,078,102

33.46%

4,078,102

33.46%

Alexander Wakeford

1,581,696

12.98%

1,581,696

12.98%

Michael Mayne

2,105,000

17.27%

2,105,000

17.27%

Creedy Carver Chickens Limited

2,271,410

18.64%

2,271,410

18.64%

 

TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:

N/A

THE EXPECTED ADMISSION DATE:

20 July 2023

 

WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:

www.blackpointbiotech.com

 

In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows:

 

UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON:

N/A

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1673521  06-Jul-2023 

fncls.ssp?fn=show_t_gif&application_id=1673521&application_name=news&site_id=symex

AQUIS STOCK EXCHANGE's latest news


15/05/2024 08:00
01/05/2024 08:00
01/05/2024 08:00
08/04/2024 08:00
04/04/2024 08:00
28/03/2024 08:00
18/03/2024 08:00
16/02/2024 08:00
29/01/2024 08:00
18/01/2024 08:00


Other stories

17/05/2024 03:30
17/05/2024 03:15
17/05/2024 06:59
16/05/2024 23:01
16/05/2024 15:10
17/05/2024 02:47
16/05/2024 22:32
16/05/2024 19:04
17/05/2024 04:53
16/05/2024 20:32
17/05/2024 05:41
16/05/2024 18:22
16/05/2024 19:04
17/05/2024 05:45
16/05/2024 23:20
17/05/2024 00:22
16/05/2024 18:28
16/05/2024 20:25
16/05/2024 17:10
16/05/2024 00:05
16/05/2024 15:39
15/05/2024 16:03
16/05/2024 18:00
17/05/2024 03:31
16/05/2024 14:00
17/05/2024 06:38
16/05/2024 23:23
17/05/2024 00:30
16/05/2024 22:54
17/05/2024 03:00
15/05/2024 11:44
16/05/2024 09:24
15/05/2024 17:00
16/05/2024 21:46
16/05/2024 13:00
16/05/2024 17:46
16/05/2024 10:15
16/05/2024 10:02